Cardiff Oncology
A clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.
Cardiff's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC).
Latest Cardiff Oncology News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze